Keros Therapeutics price target lowered to $25 from $43 at Truist

Truist lowered the firm’s price target on Keros Therapeutics (KROS) to $25 from $43 and keeps a Buy rating on the shares as part of a broader research note on Biotech. Keros is an attractive company for investors with a longer-term horizon, particularly in the context of the current macro environment and uncertainty around Biopharma, and the stock is trading below cash, the analyst tells investors in a research note. The stock is undervalued with no value to any pipeline programs or even the partnered ones, though the firm is acknowledging investor skepticism given safety concerns, Truist adds.